Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.

Background: Local priming of the innate immune system with a Toll-like receptor (TLR)2/6 agonist may reduce morbidity and mortality associated with viral respiratory tract infections, particularly for the elderly and those with chronic diseases. The objectives of the present study were to understand the potential of prophylactic treatment with a TLR2/6 agonist as an enhancer of innate immunity pathways leading to accelerated respiratory virus clearance from the upper airways.

Methods: Two randomised, double-blind, placebo-controlled clinical trials were conducted in healthy adult participants.

Head rotations follow those of a truncated Fick gimbal during an auditory-guided visual search task.

Recent interest in dynamic sound localization models has created a need to better understand the head movements made by humans. Previous studies have shown that static head positions and small oscillations of the head obey Donders' law: for each facing direction there is one unique three-dimensional orientation. It is unclear whether this same constraint applies to audiovisual localization, where head movement is unrestricted and subjects may rotate their heads depending on the available auditory information.

Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial.

Cystic fibrosis (CF) is a genetic disease caused by mutations in the (cystic fibrosis transmembrane conductance regulator) gene. Although CF is a multiorgan disease, the leading causes of morbidity and mortality are related to progressive lung disease. Current understanding of the effects of the broad spectrum of mutations on CFTR function has allowed for the development of CFTR modulator therapies.

Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy.

Rationale And Objective: Cystic fibrosis (CF) is caused by mutations in the CF Transmembrane Conductance Regulator (CFTR) gene. CFTR modulators offer significant improvements, but approximately 10% of patients remain nonresponsive or are intolerant. This study provides an analysis of rSIV.